herceptin and the brain

[Snufi]

Does Herceptin cross the brain blood barrier? A nurse I saw today says no. How does floating cancer cells in brain get killed then? Snufi

[Laurel]

Snufi,

It is my layman's understanding that the Herceptin molecules are too large to cross the BBB. They believe Tykerb does, however, but that isn't used in the adjuvant setting yet. I am relying on some homeopathic aides such as Olive oil, Borage or Primrose oils, and good old Super EPA, all off which have been shown in in vivo studies to bind to HER-2neu. Google olive oil and Her-2 and you'll find interesting studies. I figure it cannot hurt and may help.

To be perfectly candid, I feel vulnerable when it comes to my brain with this nasty foe. They are doing clinic trials with stage III bc and tykerb, so perhaps in a few years they will offer Tykerb to early stage bc patients. Until then, I suppose we just say our prayers.

[gdpawel]

A study from Dana Farber Cancer Institute identified (as many as 34%) central nervous system metastases (brain mets) in women who receive Herceptin therapy for metastatic breast carcinoma. Patients receiving Herceptin as first-line therapy may develop brain metastases while responding to or stable on Herceptin.

The research doesn't necessarily suggest that Herceptin causes breast cancer spread to the CNS, but instead that CNS mets are common to Her2-positive patients and that more than likely, because Herceptin doesn't cross the blood-brain barrier (BBB), the drug while effective outside the CNS cannot treat cancer inside the CNS, or stop it from spreading there.

Monoclonal antibodies like Herceptin are enormous. Very large molecules don't have a convenient way of getting access to the large majority of cells. Plus, there is multicellular resistance, the drug affecting only the cells on the outside may not kill these cells if they are in contact with cells on the inside, which are protected from the drug. The cells may pass small molecules back and forth (in the same way that neighbors can share food).

Exciting results have come from studies of multitargeted tyrosine kinase inhibitors, small molecules that act on multiple receptors in the cancerous cells, like Tykerb and Sutent. Maybe Tykerb or Sutent may be better than Herceptin.